Abstract:Background: The coronavirus disease 2019 (COVID-19) pandemic has had a profound impact on global health, primarily characterized by severe respiratory illness. However, emerging evidence suggests that COVID-19 can also lead to secondary sclerosing cholangitis (SC), referred to as post-COVID-19 cholangiopathy. Aim: To synthesize currently reported cases to assess the current state of knowledge on post-COVID-19 cholangiopathy. Methods: Medical Subject Headings and Health Sciences Descriptors were used to retrieve relevant studies, which were combined using Boolean operators. Searches were conducted on electronic databases including Scopus, Web of Science, and MEDLINE (PubMed). Studies published in English, Spanish, or Portuguese were included, with no restrictions on the publication date. Additionally, the reference lists of retrieved studies were manually searched. Simple descriptive analyses were used to summarize the results. Then the data were extracted and assessed based on Reference Citation Analysis (https://www.referencecitationanalysis.com/). Results: The initial search yielded a total of 192 articles. After screening, 85 articles were excluded due to duplication, leaving 107 articles for further review. Of these, 63 full-length articles met the inclusion criteria and were included in the analyses. Most of the patients were male and exhibited elevated liver function tests (93.8%). Magnetic resonance imaging revealed duct thickening with contrast enhancement (47.7%), as well as beading of the intrahepatic ducts (45.7%) with peribiliary contrast enhancement on diffusion (28.7%). Liver biopsy results confirmed SC in most cases (74.4%). Sixteen patients underwent liver transplantation, with three experiencing successful outcomes. Conclusion: Post-COVID-19 cholangiopathy is a serious condition that is expected to become increasingly concerning in the coming years, particularly considering long COVID syndromes. Although liver transplantation has been proposed as a potential treatment option, more research is necessary to establish its efficacy and explore other potential treatments.

Gallstone and Gallbladder Disease: Biliary Tract and Cholangiopathies

Consensus on the Diagnosis and Treatment of Cholestatic Liver Diseases (2015, China)

COVID-19 related biliary injury: A review of recent literature

Gallbladder and biliary pathology: lessons learned from multidisciplinary conference

COVID-19-Related Cholangiopathy: Histological Findings

Gallstones: Prevention, Diagnosis, and Treatment

Acute Cholecystitis from Biliary Lithiasis: Diagnosis, Management and Treatment

Central role for cholangiocyte pathobiology in cholestatic liver diseases

Comprehensive Review of Molecular Mechanisms during Cholestatic Liver Injury and Cholangiocarcinoma

Gallstone Disease: Common Questions and Answers

The Need for Standardizing Diagnosis, Treatment and Clinical Care of Cholecystitis and Biliary Colic in Gallbladder Disease

Post-COVID-19 cholangiopathy: Systematic review

Metabolic dysfunction-associated gallstone disease: expecting more from critical care manifestations

Liver injury in severe COVID-19 infection: current insights and challenges

Gallstones in Patients with Chronic Liver Diseases

The Multifaceted Impact of Gallstones: Understanding Complications and Management Strategies

Management of Gallstones and Acute Cholecystitis in Patients with Liver Cirrhosis: What Should We Consider When Performing Surgery?

[Gastrointestinal endoscopy in the diagnosis and treatment of biliary liver disease]

Gastrointestinal microbiome and cholelithiasis: Current status and perspectives

The gut microbiota-bile acid axis in cholestatic liver disease

Managing Gallstone Disease in the Elderly